Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

3(37.5%)

8Total

Phase 1(5)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04325594Phase 1Completed

The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure

Role: collaborator

NCT05693181Phase 1Unknown

Cord Blood Cells in Patients With Acute SCI

Role: collaborator

NCT04098029Phase 2Unknown

Estimation of the Safety and Efficiency Transfusion of HLA Matched CBU in Patients With CP

Role: lead

NCT04099381Phase 1Unknown

Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility.

Role: lead

NCT03826498Phase 2Unknown

Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy

Role: lead

NCT03786744Phase 1Completed

Allogenic Cord Blood Transfusion in Patients With Autism

Role: lead

NCT04491240Phase 1Completed

Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.

Role: lead

NCT03762967Phase 2Unknown

Autologous Adipose-Derived Adult Stromal Vascular Cell Administration for Male Patients With Infertility

Role: lead

All 8 trials loaded